
|Articles|January 6, 2005
FDA approves new oral agent for overactive bladder
The FDA has approved extended-release darifenacin (Enablex, 7.5 mg and 15 mg) for the treatment of overactive bladder.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: MDT for Oligometastatic Prostate Cancer, with Chad Tang, MD
2
Study suggests potential diuretic effect with nadofaragene firadenovec
3
Praful Ravi, MB, BChir, MRCP, on PSMA-PET during initial systemic therapy for mHSPC
4
Published data show DFS benefit with aglatimagene besadenovec in localized prostate cancer
5











